Publications, Papers and Posters

Featured:

eBioMedicine

Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study

October 29, 2025

Systemic chemotherapeutics have limited efficacy in many advanced solid tumours. This study evaluated the safety and tolerability of INT230-6, a unique intratumoural (IT) formulation of cisplatin, vinblastine, and 8-((2-hydroxybenzoyl)amino)octanoate (SHAO), an amphiphilic cell-penetration enhancer.

Intratumoral Injections of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer: Early observations from INVINCIBLE-4-SAKK 66/22 (NCT06358573), a Phase II Randomized Clinical Trial

December 2025

Accelerating an Anthracycline-Free Future: A New Drug in Clinical Testing Offers Patients Hope for Safer, More Effective Breast Cancer Therapy Combinations

December 2025

A Multicenter, Randomized, Global Phase 3 Study to Assess the Efficacy and Safety of Intratumoral (IT) INT230-6 (SHAO, vinblastine, cisplatin) as Monotherapy Compared with Standard of Care Systemic Chemotherapy in Adults with Locally Recurrent, Inoperable, or Metastatic Soft Tissue Sarcomas (STS; INVINCIBLE-3): Abstract TPS11588

May 2025

Evaluation of Pathological Complete Response (pCR) and Immunomodulatory Effects Following Intratumoral Injection of INT230-6 Prior to Neoadjuvant Immuno-chemotherapy in Early-Stage Triple Negative Breast Cancer (TNBC): A Phase II Randomized Study, the INVINCIBLE-4-SAKK 66/22 Trial. NCT06358573

December 2024

INVINCIBLE-3 STUDY: A MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF INTRATUMORAL INT230-6 COMPARED TO STANDARD OF CARE THERAPY IN SELECTED METASTATIC SOFT TISSUE SARCOMAS

November 2024

Intensity Therapeutics: a Bargain for a Late-Stage Company with a Remarkable Oncology Drug

May 2024

Intensity Rings the Nasdaq Stock Market Closing Bell

December 2023

A Phase II Randomized Window of Opportunity Trial Evaluating Cytotoxic and Immunomodulatory Effects of Intratumoral INT230-6 in Early Stage Breast Cancer: The INVINCIBLE Trial

December 2023

Abstract 1574238: Intratumoral INT230-6 (Cisplatin, Vinblastine, Shao) Alone or with Ipilimumab Prolonged Survival with Favorable Safety and Immune Activation in Adults with Refractory Sarcomas (NCT 03058289)

November 2023

Intensity Therapeutics Reports INT230-6 Can Cause Immune Priming in Historically Quiescent Breast Cancers

June 2023